KKR: creates Frontier Biosolutions with Flerie
(CercleFinance.com) - KKR has announced that, in partnership with Flerie, it has created a new global pharmaceutical services platform,
Frontier Biosolutions will invest in a portfolio of companies focused on specialized pharmaceutical services for advanced therapy customers.
Thomas Eldered will take on the role of Frontier's Executive Chairman, bringing over 34 years of expertise and drawing on his experience as co-founder of Recipharm and as a life sciences investor at Flerie.
Funds managed by KKR and Flerie, through Frontier, have invested in Coriolis Pharma.
KKR's investment will enable Coriolis to continue its expansion, particularly in the fast-growing cell and gene therapy segment, extending its range of services worldwide.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Frontier Biosolutions will invest in a portfolio of companies focused on specialized pharmaceutical services for advanced therapy customers.
Thomas Eldered will take on the role of Frontier's Executive Chairman, bringing over 34 years of expertise and drawing on his experience as co-founder of Recipharm and as a life sciences investor at Flerie.
Funds managed by KKR and Flerie, through Frontier, have invested in Coriolis Pharma.
KKR's investment will enable Coriolis to continue its expansion, particularly in the fast-growing cell and gene therapy segment, extending its range of services worldwide.
Copyright (c) 2023 CercleFinance.com. All rights reserved.